Envision pharma has acquired Alligent Biopharm Consulting, a leading medical affairs agency that develops medical communications solutions for the biopharma industry.
The deal was supported by the Halifax Group, which partnered with Envision management to provide the equity investment to facilitate the acquisition.
Brian Hepburn, CEO at Envision, said: “The addition of Alligent to the Envision Pharma Group further cements our core tenet of becoming the leading international medical affairs agency.
“By acquiring Alligent, we are able to expand the capabilities we offer to medical affairs teams to ensure optimal evidence communication and ultimate product adoption based on scientific rigor.”
Alligent’s two principals, Joe Kohles and David Thompson in a joint statement, said: “Our focus on medical strategy, coupled with Envision’s global presence and technology leadership position, offers the potential for us to expand and enrich our service breadth and offering to current and future clients alike.
“We look forward to joining the Group’s leadership team and contributing to the continued success of both Alligent and Envision.”